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The current state-of-the-art assessment of treatment response in breast cancer is based on the response evaluation criteria in solid
tumors (RECIST). RECIST reports on changes in gross morphology and divides response into one of four categories. In this paper
we highlight how dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diﬀusion-weighted MRI (DW-MRI)
may be able to oﬀer earlier, and more precise, information on treatment response in the neoadjuvant setting than RECIST. We
then describe how longitudinal registration of breast images and the incorporation of intelligent bioinformatics approaches with
imaging data have the potential to increase the sensitivity of assessing treatment response. We conclude with a discussion of the
potential beneﬁts of breast MRI at the higher ﬁeld strength of 3T. For each of these areas, we provide a review, illustrative examples
from clinical trials, and oﬀer insights into future research directions.
1.Introduction
In recent years, neoadjuvant chemotherapy has become
increasingly important for patients with operable breast
cancer requiring chemotherapy [1, 2]. There are several
important reasons for this trend. These include the potential
abilitytoreduceprimarytumorburdenandtherebyallowing
for higher rate of breast conservation surgery, as well as
earlier treatment of micrometastatic disease. Neoadjuvant
chemotherapy also provides an opportunity to evaluate (in
vivo) the response of a particular treatment on an individual
patientbasiswhichmayinformtheselectionofpostoperative
chemotherapy. Furthermore, according to National Surgical
Adjuvant Breast and Bowel Project B-18 (NSABP B-18)
results,neoadjuvantchemotherapyyieldsasurvivaloutcome
similar to adjuvant treatment in early breast cancer patient
[3]. Thus, noninvasive imaging techniques which can report
on the status of the response of breast tumors to neoadjuvant
chemotherapy is of great import.
While X-ray mammography and ultrasound imaging
play a critical role in the detection and diagnosis of breast
cancer,theydonotprovidequantitativeinformationontheir
response to therapy. Additionally, the 2D nature of planar X-
ray mammography makes it diﬃcult to interpret potentially
complex 3D tumor structures, thus severely limiting its value
in quantitative longitudinal studies. Consequently, there are
currently no radiological methods for adequately assessing
the state of breast tumors or their response to treatments2 Journal of Oncology
to guide clinical decisions. Although serial biopsies may be
obtained to measure changes at the cellular and molecular
levels, the spatial sampling may be poor and the results
misleading [4–7]. Clinical judgments using physical exam-
ination, mammograms and ultrasound to measure short-
term treatment eﬀects have a high inter-observer variability
and are prone to error. The development of appropriate
methods of tissue characterization that could be applied
early in the course of treatment to assess response would
allow clinicians to individualize therapy based on each
patient’s response to aparticular agent.Quantitative imaging
techniques which can reliably assess tumor response are
urgently needed to improve clinical breast cancer care.
Three generations of solid tumor response criteria have
been applied to assess treatment response in breast cancer
clinical trials. The original WHO criteria developed in 1981
used the sum of two-dimensional measurements of cancer
lesions to compute a composite estimate of tumor burden
while the currently accepted standard method Response
Evaluation Criteria in Solid Tumors (RECIST) uses single
dimensional measurements as measured by ultrasound, X-
ray-computed tomography (CT), or magnetic resonance
imaging (MRI). While details of the criteria are presented
elsewhere [8], we brieﬂy summarize the salient features here.
In the pretreatment scan, “target lesions are identiﬁed”
and their longest dimension and perpendicular short axis are
measured. For lymph node lesions, the short axis is used for
the composite tumor burden score while the long axis is used
for nonlymph node lesions. The “baseline sum diameters”
are then deﬁned by adding the single dimension measure-
ment of all the target lesions. Additional scans are performed
after treatment and analyzed similarly. The percent change
in the sum of diameters from the baseline assessment to the
follow-up assessment after treatment is calculated and this
quantity is used to classify response. A complete response
(CR) is deﬁned as the disappearance of all target lesions; a
partial response (PR) is deﬁned as a 30% decrease in the
sum of diameters of the target lesions; progressive disease
(PD) is deﬁned as a 20% increase in the sum of diameters of
the target lesions or the appearance of any new lesions; and
stable disease (SD) is deﬁned as changes that do not meet
the previous three criteria. While many clinical trials have
used these criteria for assessing cancers at many disease sites
(see [9] and references cited therein), it is well recognized
that this approach needs to be signiﬁcantly improved for
a number of reasons including practical, technical, and
scientiﬁc issues. Practical and technical issues included how
to select the total number of lesions to include in the sum
longest dimension calculation, and how to apply RECIST in
trials where progression, and not response, is the primary
endpoint. However, more fundamental (scientiﬁc) issues
have also been raised, including whether or not to include
emerging imaging techniques such as, ﬂuorodeoxyglucose
PET (FDG-PET) or dynamic contrast-enhanced MRI (DCE-
MRI) with RECIST. A second fundamental issue is whether
RECIST should be included—or if it is even relevant—in
assessing the activities of noncytotoxic anticancer drugs. The
metric for positive response is based only on anatomical and
morphological changes which are (temporally) downstream
manifestations of underlying pathophysiological changes
which may occur earlier. The current (and presumably many
future) generations of anticancer therapy use molecularly
targeted agents, so changes in morphology may not be the
most appropriate method to assess response.
Response criteria continue to evolve and require vali-
dation as new technologies for assessing disease emerge. In
early 2009, RECIST was updated, as RECIST 1.1, and made
substantial progress towards addressing these (and other)
issues [9]. A major development was the incorporation of
ﬂuorodeoxyglucose positron emission tomography (FDG-
PET) in the guidelines, albeit in the limited role of assessing
progressive disease. This is at once exciting and sobering;
exciting in the sense that this is the ﬁrst time the working
group has incorporated a nonanatomical imaging modality
in the assessment of tumor response, a trend that will
almost certainly continue in the future. However, it is
also sobering because FDG-PET was ﬁrst employed in a
human imaging study in 1976 [10] and required 33 years
to advance to the point that it could be recommended as
a method for assessing one aspect (i.e., progressive disease)
of tumor response. In part, this is due to the diﬃculty in
developing,optimizing,andstandardizingadvancedimaging
techniques to permit results to be obtained and compared
across vendors and sites. In light of this, the RECIST working
group concluded that “there is not suﬃcient standardization
or evidence to abandon anatomical assessment of tumor
burden”. Nonetheless, it makes clear that more advanced and
speciﬁc imaging methods will be incorporated into RECIST
infutureyearsandthisfactisnotlostonthePETcommunity
who has begun to formulate the PET Response Criteria in
Solid Tumors, or “PERCIST” [11].
Clearly, methods are needed to characterize the underly-
ing pathophysiological changes induced by speciﬁc targeting
agents. Such methods may be considerably more likely to
oﬀer earlier—and more speciﬁc—information on response
to treatment when compared to changes in longest tumor
dimensions. This may be especially true in the case of
neoadjuvant treatment of breast cancer. Neoadjuvant treat-
ment oﬀers a unique opportunity for correlation of image-
based changes in tumor burden with the pathologic response
observed at the time of deﬁnitive surgery. Pathologic com-
plete response is highly predictive of survival in breast cancer
and oﬀers an earlier endpoint for preliminary validation
of image-based response criteria. Several aspects of MRI
data analysis, acquisition, and synthesis have matured to the
pointwheretheycanoﬀerquantitativeinformationonbreast
tumor status and response to therapy.
In this contribution, we begin by deﬁning what is meant
by “quantitative imaging” and then proceed to review both
diﬀusion weighted MRI (DW-MRI) and dynamic contrast-
enhanced MRI (DCE-MRI). We then proceed to discuss
how these techniques can best be synthesized (through
image registration and the incorporation of bioinformatic
approaches) to oﬀer optimal insight into treatment eﬀects.
In each section we introduce the basis of the technique,
oﬀer several illustrative examples, and then highlight areas
for further research. We conclude with a discussion of
what high magnetic ﬁeld scanners (3T), which are graduallyJournal of Oncology 3
permeating clinical practice, can oﬀer for the quantitative
imaging of breast cancer.
2.Beyond SignalIntensity:
QuantitativeImaging
Any digital image, regardless of whether it was acquired with
acommoncameraorasophisticatedmedicalimagingdevice,
consists of a matrix of signal intensities. In the case of a
photograph captured with a camera, the signal intensities
in each pixel are given by a combination of the colors red,
green, and blue, whereas in a medical image, the displayed
signal intensity can be made proportional to one or more
physical or physiological properties of tissue. In standard
of care clinical imaging, the signal intensities in each voxel
are acquired in such a way so as to optimize the contrasts
between diﬀerent tissue types. This improves the ability of a
clinician to detect abnormalities and allows for investigators
to apply the RECIST criteria described above. However, the
signal intensities are usually a complicated mixture of several
diﬀerent quantities related to both physiology and scanner
characteristicsthatdonothavephysicalunitsassociatedwith
them.
Quantitative imaging connotes techniques in which the
signal intensity in each voxel does have physical units
and is therefore associated with a particular physical or
physiological phenomenon. For example, there are tech-
niques available that report on tissue oxygen status, blood
ﬂow, or metabolism; in each of these cases, the signal
intensities within the image can be made proportional to
mmHg, mL(blood)/mL(tissue)/min, and the rate of glucose
metabolism, respectively. Quantitative cancer imaging is
motivated by the hypothesis that changes in morphology
are only the downstream manifestations of underlying
pathophysiological changes (such as those just above), but
that if it were possible to reliably measure more relevant
properties we would be able to assess treatment response
at an early stage and ultimately, perhaps, contribute to
individualized patient care. Given the fact that anticancer
treatments are increasingly speciﬁc, it is necessary to develop
diagnostic techniques that can report on the speciﬁc eﬀects
of those treatments.
3.DCE-MRI
3.1. Fundamentals of DCE-MRI. DCE-MRI involves the
rapid acquisition of images before, during, and after the
injection of a contrast agent (CA). MRI CAs are pharmaceu-
ticals administered to patients that are designed to increase
the contrast between diﬀerent tissues by changing a tissue’s
inherent relaxation times, T1 and/or T2. These relaxation
properties reﬂect the time it takes for the nuclear magne-
tization, induced by the external polarizing magnetic ﬁeld,
to recover back towards equilibrium after being disturbed
by radiofrequency emissions during the MRI process. The
most common MRI CAs are gadolinium-chelates such as,
Gd-DTPA. In a typical DCE-MRI imaging session, a region
of interest (ROI) is selected for study (e.g., a tumor locus),
and a series of heavily T1-weighted MR images are collected
before, during, and after a CA is injected into the antecubital
vein of a patient. Each image in the series corresponds to
one time point, and each pixel in each image set gives rise to
its own signal intensity time course which can be analyzed
mathematically. In general, quantitative analyses are based
on compartmental modeling whereby the tissue within the
tissue element corresponding to each voxel is divided into
a series of partitions, between which contrast agent may
move back and forth. In the case of DCE-MRI, each voxel
is typically assumed to consist of two compartments, the
vascular space and the extravascular space. By considering
therateofchangeoftheconcentrationofCAinextravascular
space, we can write down the following model:
d
dt
Ct(t) = k1Cp(t) −k2Ct(t),( 1 )
where Ct(t)a n dCp(t) are the time course of concentrations
of CA in the tissue and plasma space, respectively, and k1
and k2 are the rate constants describing the exchange of the
CA from plasma to tissue and tissue to plasma, respectively.
By convention, Ktrans and ve denote the volume transfer
constant and the volume of extravascular extracellular space,
respectively. It can readily be shown [12] that k1 = Ktrans and
k2 = Ktrans/ve. With these assignments, (1) (details provided
in [12]) has the following solution:
Ct(T) = Ktrans
 T
0
Cp(t)exp

−
Ktrans
ve(t −T)

dt. (2)
Equation (2) is frequently referred to as the standard model
and can be extended to include a vascular component
explicitly in which case the model is given by (3)
Ct(T) = Ktrans
 T
0
Cp(t)exp

−
Ktrans
ve(t − T)

dt +vpCp(T),
(3)
where vp is the plasma volume fraction. In situations where
the blood plasma volume is very small (say, less than 2%),
(2) may be adequate to assess the DCE data. However, as vp
gets larger, (2) becomes less applicable and (3)i sp r e f e r r e d .
Of course, ap r i o r i , the approximate plasma volume of the
tumor may not be known and that is why many investigators
prefer using (3) to ﬁt DCE time courses.
The potential clinical utility of Ktrans and vp is that they
oﬀer the ability to noninvasively and quantitatively report
on tumor vascular status; Ktrans estimates tumor vessel blood
ﬂow and permeable, while vp reports on the volume fraction
of a section of tissue that consists of blood. Both of these
measures can be used in studies wherein the therapy is
designed to aﬀect tumor vascular status. Changes in the
extravascular extracellular volume fraction (as estimated
by ve) are more complicated to interpret as there are many
treatments that might change the volume and geometry of
this space. Most studies that employ DCE-MRI to assess
treatment response focus on Ktrans and vp.
In order to perform quantitative DCE-MRI analysis, the
time courses of Ct(t)a n dCp(t) must be estimated, then
those time courses can be input into a curve-ﬁtting routine4 Journal of Oncology
to extract Ktrans, vp,a n dve on a voxel-by-voxel or region-of-
interest basis. Figure 1 presents an example of this approach.
In DCE-MRI this is not a straightforward process because
the CA is not directly measured—only its aﬀect on the
tissue’s native T1 relaxation is measured in the study. Thus,
the MR signal time course must be converted to a time
course representing the concentration of CA. The majority
of studies employ (4) for this transformation:
R1 = r1Cx +R10,( 4 )
where R1 = 1/T1, r1 is the relaxivity of the CA (which
measures the eﬃcacy of the CA at enhancing relaxation in
unitsofmM−1s−1),Cx isCt orCp,andR10 =1/T10,wher eT10
is the longitudinal relaxation time prior to administration
of CA. Equation (4) assumes that the extravascular space
is a homogeneous solution and that the system remains in
what is called the “fast exchange limit” (FXL) with respect
to the water exchange between the extravascular extracellular
space and the extravascular intracellular space. In most
tissues, most water is intracellular, and because the com-
mon Gadolinium chelates cannot access this intracellular
water directly, water exchange between the extravascular
extracellular space and the extravascular intracellular space
must be explicitly incorporated into analytic models under
certain circumstances [13, 14]. Similar comments apply to
water exchange between the intravascular and extravascular
spaces when using an intravascular agent [15]. In these cases,
longitudinal relaxation may exhibit a recovery that is not
well described by a single exponential or single time constant
as discussed by several investigators [16–18]. The eﬀects of
slower water exchange may be incorporated into analyses
of the MRI signal and then the longitudinal relaxation can
often be characterized as exhibiting a bi-exponential decay.
More speciﬁcally, the signal intensity equation in a spoiled
gradient recalled echo acquisition (the main choice for DCE-
MRI studies) is given by
S
S0
=
1 −exp(−TR/T1) ·sinα
1 − cosα ·exp(−TR/T1)
,( 5 )
where α is the ﬂip angle, S0 is a reference signal that depends
on the scanner gain and proton density, TR is the repetition
time, and we have assumed that the echo time (TE)i s
much less than the apparent transverse relaxation rate T2
∗.
However, in the case of bi-exponential decay of longitudinal
relaxation, (5)m u s tb ea m e n d e dt o
S
S0
= aL
1 −exp(−TR/T1L) · sinα
1 − cosα ·exp(−TR/T1L)
+aS
1 −exp(−TR/T1S) · sinα
1 −cosα · exp(−TR/T1S)
,
(6)
where aL and R1L are the fraction and relaxation rates,
respectively, for the component with the longer T1
(i.e., R1L ≡ 1/T1L); aS and R1S are deﬁned similarly for the
component with the shorter T1. Furthermore, instead of (4)
we have
1
T1S,1L
=
1
2

1
T1A
+
1
τA
+
1
T1B
+
1
τB

±
1
2

1
T1A
+
1
τA
+
1
T1B
+
1
τB
2
−

1
T1A
+
1
τA

1
T1B
−
1
τB

−
1
τAτB
1/2
,
(7)
where T1A and T1B are the relaxation times for components
A and B,r e s p e c t i v e l y ,τA denotes the average lifetime of
a water proton in compartment A,a n dτB denotes the
average lifetime in the compartment B. In this formalism
the extravascular extracellular space can be taken to be
compartment A while the extravascular intracellular space
can be taken to be compartment B. The pharmacokinetic
parameters obtained using (2), (4), and (5)( o r( 3), (4),
and (5)) and those extracted by (2), (6), and (7)m a y
diﬀer signiﬁcantly [14, 19–21] and these diﬀerences have a
signiﬁcant eﬀect on establishing if a tumor is responding
to treatment. However, there is some disagreement as to
whether this formalism is truly justiﬁed in a standard DCE-
MRI study and it is therefore an active area of investigation
[22].
The various models have their respective strengths and
weaknesses; the FXL models with and without a vp term
are straightforward to apply, but may not be as physically
accurate as the exchange models. However, the exchange
models require specialized data (high temporal resolution
and high signal-to-noise data) that may not always be
available in the clinical setting. Determining the optimal
DCE analysis method for breast studies is an area of active
investigation.
3.2. DCE-MRI in Breast Cancer Clinical Trials. A consid-
erable number of studies of cancer have applied DCE-
MRI methods but have employed only qualitative or semi-
quantitative analyses of these data, that is, the investigators
did not perform complete modeling, rather they studied
features such as, the volume of the enhancing region and
the area under the signal intensity time course, and so
forth. There have been substantially less studies that have
included quantitative modeling of DCE-MRI time courses
(see, e.g., [23–25]), and when quantitative models have been
employed, diﬀerent authors have not always shown similar
results.
To date, the most complete study of contrast-enhanced
MRI in assessing the response of breast tumors to therapy
was reported by Ah-See et al. [26] who applied both DCE-
MRI and dynamic susceptibility MRI (DSC-MRI, for a
review see [27]). The authors studied the ability of Ktrans,
kep (≡ Ktrans/ve), ve, maximum contrast agent concentration,
relative blood ﬂow, relative blood volume, and mean transit
time to predict treatment response in 28 patients receivingJournal of Oncology 5
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Figure 1: (a) and (b) display pre-contrast and postcontrast T1-weighted sagittal images of a breast tumor. By considering the time course
from each voxel, a parametric map can be generated that reports on, for example, the volume transfer constant (Ktrans) as displayed in (c).
5-ﬂuorouracil, epirubicin and cyclophosphamide neoadju-
vant chemotherapy. While all parameters correlated with
pathological response, Ktrans was the best predictor with an
area under the receiver operating characteristic curve of 0.93
while changes in tumor size did not predict for pathologic
response. This is a notable result because it oﬀers evidence of
an emerging functional imaging technique that outperforms
conventional morphological imaging.
However, a similar study by Yu et al. reported somewhat
diﬀerent results [28]. These investigators studied the ability
of tumor size, Ktrans and kep to predict ﬁnal clinical response
based on changes after two and four cycles of anthracycline
and cyclophosphamide neoadjuvant chemotherapy in 29
patients with invasive breast cancer. While there was a
signiﬁcant correlation between tumor size and the pharma-
cokinetic parameters, the area under the receiver operating
characteristic curve diﬀerentiating between nonresponders
and responders was 0.88, 0.77, and 0.63 for tumor size,kep,
and Ktrans, respectively. The authors concluded that early
tumor size changes on MRI after one cycle of therapy
provided the most accurate predictor in assessing response
to this treatment regimen.
The reasons for such discrepancies are not entirely clear
but almost certainly related to the diﬀerences in treatment
regimen and data acquisition techniques and timing of the
second imaging session. (The two groups actually used very
similar analysis techniques based on (2) described above.)
In particular, Ah-see et al. acquired the second imaging data
set after the second cycle of therapy, while Yu et al. acquired
the second imaging data set after the ﬁrst cycle of therapy.
It is possible that the changes observed by the two groups
are due to the timing of the second imaging session. Also,
of particular interest is the issue of temporal resolution and
contrast agent injection rate. Ah-See et al. acquired data with
a temporal resolution of 12 seconds during their dynamic
study after injection of 0.1mmol/kg of Magnevist (Bayer
Pharmaceuticals)at4mL/sec,whereasYuet al.acquireddata
with a 42-second temporal resolution after the injection of
0.1mmol/kg of Omniscan (GE Healthcare) at the rate of
approximately 1mL/sec. (As we will see below, the issue of
temporal versus spatial resolution is of critical importance
and is a diﬃcult balancing act.) The accuracy of estimating
Ktrans is determined by the initial rapid changes of the
signal intensity time course so if the curve is not sampled
adequately errors in Ktrans may result [29]. It is possible that
the diﬀerences in temporal resolutions and injection rates
led to the diﬀerences in Ktrans estimates, and it is generally
appreciated that diﬀerences in acquisition protocol can lead
to substantially diﬀerent outcomes [30].
3.3. Research Opportunities in DCE-MRI of the Breast. As
described in Section 3.1, there are a number of methods
available for both data acquisition and analysis in a DCE-
MRIstudyandtheoptimalmethodshaveyettobeidentiﬁed.
For DCE-MRI to have the broadest impact, it will be
necessary to establish the most accurate and precise methods
for assessing treatment response. It is imperative, particulary
when performing multi-institutional studies, to have a
standard technique in place for which reproducibility at each
site has been established. A particular aspect of the analysis
that must be addressed is that of the arterial input function.
Before a curve ﬁtting routine can be employed to extract
the pharmacokinetic parameters discussed above, the time
rateofchangeoftheconcentrationofCAinthebloodplasma
(Cp), which is typically called the arterial input function
(AIF), must be established. This time course changes very
rapidly, so images have to be acquired with high temporal
resolution, but when images are acquired quickly there
is a net decrease in signal-to-noise ratio and/or spatial
resolution. The need to acquire high temporal resolution
data conﬁnes quantitative DCE-MRI in two fundamental
ways. The ﬁrst limitation is that it limits the ability to probe
tumor heterogeneity and scan large sections of tissue at
high resolution. The second limitation is that high temporal
resolution acquisitions limit the clinical adoption of the
technique because high spatial resolution data covering
large sections of tissue are required for clinical reading and
applying the RECIST criteria; in particular, high temporal6 Journal of Oncology
resolution data is usually limited to scanning one breast
which contrasts with the clinical aim of examining both
breasts. Some investigators have attempted to overcome this
problem by using a population-based AIF [31, 32], reference
region models [33, 34], or keyhole imaging techniques [35,
36]. Currently, there are three major kinds of AIFs employed
in breast studies, in increasing order of diﬃculty to obtain,
these are: (1) a bi-exponential decay model; (2) a population
based AIF, or (3) an individually measured AIF. The ﬁrst of
these does not require any new data acquisition or analysis,
while the second method requires measurement of the AIF
in a suitable population of patients or volunteers. The third
method is the most complex but also (potentially) the most
accurate. Using a model or population based AIF reduces the
demands on the data acquired, but if there is a substantial
diﬀerence between the model or population AIF and an
individual’sAIFthenthismayleadtosigniﬁcanterrorsinthe
pharmacokinetic parameters returned from such an analysis.
The accurate characterization of the AIF represents an aspect
of breast DCE-MRI that could beneﬁt from further research.
4. DW-MRI
4.1. Fundamentals of DW-MRI. The contrast mechanism
behind DW-MRI is based upon the eﬀects of tissue
microstructures and organization on the self-diﬀusion of
water. The random motions of water molecules, also known
as Brownian motion, are due to thermal energy and were
ﬁrst analyzed mathematically by Einstein [37]. For freely
diﬀusing molecules, the distribution of displacements that
the particles will experience over a given amount of time (t)
is described by a Gaussian function. The standard deviation
is determined by the distribution which is deﬁned by the
diﬀusion coeﬃcient (D) of the molecules, which depends
upon the temperature, the size of the particle, and the
viscosity of the medium. The mean-squared displacement of
the molecules in one dimension over the diﬀusion time t is
given by the equation

x2
= 2Dt. (8)
For example, free diﬀusion of water molecules at nor-
mal body temperature, with a diﬀusion coeﬃcient of
3×10−3 mm2/s, would result in an average displacement of
17–25μm in one dimension over diﬀusion times of 50–
100ms.However,watermoleculeswithintissuearenotfreely
diﬀusingonthistimescale.Theyencountermacromolecules,
cellmembranes,andothertissuemicrostructuresthathinder
diﬀusion, causing a reduction in the average diﬀusion
displacement, compared to that of free water. This eﬀective,
or apparent diﬀusion coeﬃcient (ADC) can be measured
with DW-MRI [38].
The signal intensity for each voxel acquired in DW-MRI
is dependent on the apparent diﬀusion coeﬃcient of water
(wenowusethetermDinterchangeablywithADC inasingle
direction), the signal acquired with no diﬀusion weighting
(S0), and a diﬀusion-weighting factor, b [39]:
S = S0exp(−bD),( 9 )
where
b = γ2δ2G2

Δ −
δ
3

, (10)
γ isthegyromagneticratioofprotons,δ isthedurationofthe
diﬀusion-weightinggradientG,andΔisthetime(equivalent
to t in (8)) over which diﬀusion eﬀects on the MRI signal are
manifest.
The value of b is known and determined by the imaging
parameters. Therefore, only two images, one nondiﬀusion-
weighted image (G = 0) and one diﬀusion-weighted image
(G>0) are needed to obtain S0 and S,r e s p e c t i v e l y ,a n d
to calculate a map of D in a single direction. In practice,
however, it is common to apply diﬀusion-weighting in three
orthogonal directions (i.e., x, y,a n dz)w h e r eGx = Gy = Gz >
0. The ADC maps calculated from the three images are then
averaged to obtain a mean ADC map, reducing the eﬀects of
anisotropic diﬀusion.
4.2. DW-MRI in Breast Cancer Clinical Trials. Tumors
typically exhibit decreased ADC values compared to the
surrounding unaﬀected tissue because of their increased
cellularity [40–42] (e.g., see Figure 2). The sensitivity of
DW-MRI to these changes in tissue microstructure and
organization has led to increasing interest in the potential of
ADC measurements as a biomarker for diagnosis of cancer,
tumor diﬀerentiation, and treatment assessment. Preclinical
studies of the eﬀects of successful treatment on tumor
ADC values produced provocative results. For example,
Galons et al. [43] demonstrated that successful treatment of
human breast cancer xenografts with Paclitaxel resulted in
a signiﬁcant increase in tumor ADC within just two days
of the initiation of treatment, and these changes preceded
signiﬁcant reductions in tumor volume.
Although there have been few clinical studies of the
eﬀects of treatment on tumor ADC in breast cancer
published to date, the results of the existing studies are
promising. In a study of 11 women with biopsy-proven inﬁl-
trating breast cancer undergoing neoadjuvant chemotherapy
(Taxotere or adriamycin/Cytoxan), Yankeelov et al. reported
that the mean tumor ADC value increased signiﬁcantly (P =
.005) by 24% after a full course of chemotherapy [44].
While this study suggests that ADC may be a useful imaging
biomarker for assessing overall response to therapy in breast
tumors, it does not provide insight into its usefulness as an
early biomarker. Evidence of early changes in ADC due to
treatment was reported by Pickles et al. [45]. In this study,
bothtumorlongestdiameterandADCvaluesweremeasured
in eight women with biopsy-proven invasive breast cancer
who were undergoing neoadjuvant chemotherapy (four
cycles of epirubicin and cyclophosphamide). Measurements
were made prior to the start, after the ﬁrst cycle, and after
the second cycle of therapy. A signiﬁcant increase (14%,
P = .005) in mean tumor ADC was observed after a
single cycle of chemotherapy, while tumor longest diameter
remained relatively unchanged (−1%, P = .852). After
two treatment cycles, the tumor longest diameter began to
approach a signiﬁcant decrease (−20%, P = .057) comparedJournal of Oncology 7
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Figure 2: ADC values are reduced in breast cancer tumors compared to the unaﬀected tissue. Shown here is a postcontrast T1-weighted
image (a) for reference and an overlay of the corresponding ADC map (b). The tumor, located above and between the biopsy clips (white
arrows), exhibits increased signal in the T1-weighted image and decreased ADC values, compared to the surrounding tissue.
to the pretreatment value, and the mean ADC value was 27%
higher than the pretreatment value (P = .004).
More recently, Sharma et al. [46] compared tumor
ADC values at multiple time points throughout the course
of therapy in a study of 56 women with cytologically
proven inﬁltrating ductal carcinoma undergoing neoadju-
vant chemotherapy (cyclophosphamide, adriamycin (dox-
orubicin) and 5-ﬂuorouracil (5-FU); cyclophosphamide,
epirubicin and 5-FU; or paclitaxel and epirubicid). ADC
measurements were made before, after the ﬁrst cycle, after
the second cycle, and after the third cycle of treatment,
although not all participants were able to be scanned at all
four time points. Overall, the mean tumor ADC increased
signiﬁcantly (P<. 01) from 0.95 ± 0.11 × 10−3 mm2/s
(N = 53) before treatment to 1.09 ± 0.16 × 10−3 mm2/s
(N = 14) after 1 treatment cycle. In the 11 patients scanned
both before treatment and after one treatment cycle, tumor
ADC increased signiﬁcantly (P = .002) from 1.01 ± 0.07 ×
10−3 mm2/s before treatment to 1.15 ± 0.13 × 10−3 mm2/s.
Mean tumor ADC continued to increase signiﬁcantly (P<
.01) throughout treatment to 1.21 ± 0.22 × 10−3 mm2/s
(N = 24) after the second treatment cycle and 1.30 ± 0.24 ×
10−3 mm2/s (N = 29) after the third treatment cycle. Tumor
diameterandvolumereductionswereobservedonlyafterthe
second cycle of treatment. The authors suggest that changes
in ADC may be more useful for personalized treatment
management than the current standard of changes in tumor
morphology.
4.3. Research Opportunities in DW-MRI of the Breast. While
the results of the DW-MRI studies mentioned in the
previous section are encouraging, the application of DW-
MRI in breast cancer is still relatively new and there are
several technical challenges that need to be addressed. First,
the chemotherapy agents used in these studies were all
cytotoxic. Successful treatment with these agents leads to
cell death, ultimately increasing the extracellular volume
and/or reducing the cell density within the tumor, which
w o u l db ee x p e c t e dt ol e a dt oa ni n c r e a s ei nt h et u m o rA D C .
The eﬀects of hormonal treatments and antiangiogenic and
cytostatic chemotherapy agents on the tumor ADC are not
fully understood yet and need to be explored.
Timing of the ADC measurements is another issue that
has not been fully addressed yet. In preclinical studies, a
signiﬁcant increase in ADC in response to treatment has
been measured in as few as two days [43]. However, the
earliest posttreatment measurements in the clinical studies
mentioned above were acquired after the ﬁrst course of
treatment, typically three to four weeks after the start of
treatment [45, 46] .T h ec o u r s eo ft u m o rA D Cc h a n g e so v e r
timeisnotfullyunderstood.Forexample,tumorADCvalues
may initially increase as tumor cells die and then decrease as
healthy tissue replaces it.
Cardiac, respiratory, and bulk subject motion during
diﬀusion-encoding can introduce artifacts into the images
and lead to inaccurate ADC measurements. To avoid this,
a fast imaging technique called echo planar imaging (EPI)
[47] is typically employed. Unfortunately, EPI is prone to
severe image distortions at the interface of materials with
diﬀerent magnetic susceptibilities, such as, the air/tissue and
adipose/glandular tissue interfaces in the breast and chest
wall. Alternative fast image acquisition schemes, such as
fast spin echo (FSE) [48], which are not as susceptible to
these distortions can be used to prevent them. However,
these alternative acquisition schemes are more prone to
motion-induced artifacts and often require the collection of
additional images to correct the motion-induced artifacts.
Susceptibility-induced distortions can be corrected using
image post-processing techniques; however, this requires the
acquisition of an accurate map of the main magnetic ﬁeld
[49].
Subjectmotionbetweentheacquisitionofslicesordiﬀer-
ent diﬀusion-weightings can cause misregistration between
the nondiﬀusion-weighted and diﬀusion-weighted images,8 Journal of Oncology
leadingtoerrorsintheADCcalculation.Multiplerepetitions
are often acquired and averaged to increase signal to noise,
and misregistration between the individual images will
also lead to inaccurate ADC calculations. Slice-based aﬃne
registration of the individual diﬀusion-weighted images to
the nondiﬀusion-weighted image is typically used in DW-
MRI studies of the brain. Until recently, however, these
techniques have not been used in DW-MRI studies of the
breast [50].
Although guidelines have been published [51], little
consensus exists yet within the ﬁeld regarding the optimum
set of b-values that should be used in DW-MRI of breast
cancer. Blood ﬂow in the capillaries causes an artiﬁcial
decrease in signal at very low b-values (e.g., 0–100s/mm2).
This eﬀect is related to the perfusion fraction, which is
the fraction of total water located within the capillaries
in the tissue [52]. Tumors typically exhibit a broad range
of perfusion factors (20%–80% [53, 54]), increasing the
eﬀects of perfusion on the signal measured at low b-values.
Therefore, values of 50–100s/mm2 are typically used instead
of b = 0s/mm 2 in cancer applications. At higher b-values
(e.g., ≥3000s/mm2), there is greater signal attenuation due
to diﬀusion and the measured signal may appear to be
artiﬁcially increased by rectiﬁed noise in magnitude images
as the noise ﬂoor is reached. The rate at which the noise
ﬂoor is approached is related to the ADC value; the higher
the ADC value, the faster the signal is attenuated at a lower
b-value. Therefore, the optimal high b-value for estimation
of ADC values is related to the ADC value of the tissue
being probed. A wide range of high b-values were used in the
studies described in Section 4.2 (300–1000s/mm2). The use
of multiple b-values can mitigate this confusion but requires
additional images and therefore takes more time.
In addition to the technical challenges of DW-MRI
acquisition, there exist challenges related to the analysis
methods used in longitudinal studies of ADC. The most
common method is region-of-interest (ROI) analysis, where
ADC values are averaged over a manually deﬁned set of
voxels within the tumor. These mean ADC values are
then compared between measurements. This method is
straightforward and relatively easy to implement. However,
it is prone to partial volume eﬀects and inter- and intrauser
errors in ROI selection. Voxelwise statistical comparisons
may provide a better means of analyzing tumors, particularly
if the tumors exhibit heterogeneous ADC values. Ma et al.
[55] recently applied a Voxelwise analysis method called
“functional diﬀusion mapping” (fDM) in a small study
evaluating early treatment response in breast cancer. Voxel-
based analyses require coregistration of images over time,
and there are several challenges to doing this, which will be
described in more detail in the next section.
5. LongitudinalRegistration of Breast Images
5.1. Fundamentals of Image Registration. Image registration
is the process of calculating a transformation to align one
image to a target image. It has been widely used in the ﬁeld
of medical image analysis to, for example, integrate com-
plementary information from multiple modalities, estimate
the variations in anatomical structures within a population,
follow diseases over time, or detect tumor response to
therapy.
Two key elements are involved in image registration:
calculation of a function which measures the similarity
between two images such as their mutual information or
a cost function that quantiﬁes diﬀerences, and a transfor-
mation which maps corresponding points of two images.
The goal of registration is to ﬁnd an optimum trans-
formation which matches two images maximally through
minimizing/maximizing the cost/similarity function. The
transformation is usually categorized as rigid, aﬃne, or
nonrigid. Only rotation and translation are involved in
rigid body transformation, while there are additional scaling
and shearing parameters in aﬃne transformation. Nonrigid
transformation is used to incorporate additional local elastic
deformations. In general, nonrigid deformation ﬁelds can be
modeled by a linear combination of basis functions which
can be expressed in various ways [56–62], cubic B-splines
[59,60],orWu’scompactlysupportedpositivedeﬁniteradial
basis functions [61, 62].
Parametric registration methods can be classiﬁed as
point-based, surface-based, or intensity-based. Point-based
registration algorithms require identifying and localizing
ﬁducial points in two images. Fiducial points can be markers
placed in images intentionally for easy identiﬁcation or
salient points in anatomical structures. The cost function
could be the distance between two sets of points (e.g., for
rigid body registration) or with additional constraints (e.g.,
ap e n a l t yt e r m[ 63] to regularize the transformation in
nonrigid registration). The rigid or aﬃne transformation
parameters or the coeﬃcients of basis functions need to
be calculated through optimizing the cost function during
registration.
Surface representation needs to be determined ﬁrst and
then registered in surface-based registration methods. The
representation includes salient points, boundaries or curves
of anatomical structures, or regions with homogeneous
intensities. Various surface-based registration algorithms
have been developed. The iterative closest point (ICP) [64]
is one of the most robust methods applied widely for
the rigid body registration of medical images. This algo-
rithm minimizes the diﬀerences between two sets of points
and calculates the transformation iteratively. The robust
point matching (RPM) algorithm [65] is another approach
commonly used in nonrigid registration tasks. Instead of
generating a one-to-one correspondence between two sets
of points as in ICP, RPM builds a “fuzzy” correspondence
matrix whose elements are weights assigned to each point in
oneimage,correspondingtoeachpointintheotherimage.A
virtualcorrespondenceisthencalculatedbasedonthematrix
and the TPS based transformation is obtained iteratively.
Intensity-based registration methods employ the image
intensity of each pixel (or voxel) to conduct the alignment,
thus containing more comprehensive information than
point- and surface-based registration. Among numerous
cost or similarity functions, mutual information (MI) and
normalized mutual information (NMI) [66–68] are the most
common approaches in medical image registration [69–72].Journal of Oncology 9
MI measures the statistical dependence between two images,
instead of using the image intensity directly. NMI is less
sensitive to the overlap size between two images than MI
[68]. MI or NMI has been employed widely as a successful
similarity function and can be extended to solve more
registration problems.
The MI-based rigid registration algorithm has been
proposed to calculate rigid body transformation through
maximizing MI using Powell’s optimization method [71].
One of the representative MI-based nonrigid registration
algorithms [73] combines a global transformation (rigid or
aﬃne) and a local transformation (the B-spline-based free
form deformation) to model the deformation ﬁeld. The cost
function is composed of a similarity term (NMI) and a
smoothness term (the bending energy [63]) and optimized
using the gradient descent technique. The method was
applied to breast MR images and then evaluated by a ﬁnite
element method- (FEM-) based validation algorithm [74].
Another popular MI-based nonrigid registration algorithm
is the adaptive bases algorithm (ABA) [61]. Wu’s [62]
radialbasisfunctionsarecompactlysupportedandemployed
to compute the transformation. The coeﬃcients of basis
functions are searched using a gradient descent algorithm
combined with a line minimization algorithm.
In addition to parametric registration algorithms, med-
ical images can also be aligned using nonparametric algo-
rithms, such as the hierarchical attribute matching mech-
anism for elastic registration technique [75], Maxwell’s
demons-based registration [76], or ﬂuid registration [77].
Those techniques compute the entire deformation ﬁeld
without using basis functions.
5.2. Review of the Literature. Although RECIST is the most
widely used approach to measure tumor response, it has
well-recognized deﬁciencies including discarding important
tumor spatial information. This is also true of methods
whichreportthemean,skewness,orkurtosisof,forexample,
a Ktrans distribution. The registration of longitudinal breast
cancer images is an alternative approach which may allow for
quantitative assessment of changes in tumor characteristics
on a voxel-by-voxel basis. However, there are only a few
investigations regarding the registration of longitudinal
breast images, although there are a number of methods
and techniques which have been developed to register a
variety of imaging data. Registering breast images presents
an u m b e ro fd i ﬃculties that are not necessarily encountered
in the registration of other organs. The challenges include
bulk breast motion and deformation caused by patient
repositioning, in addition to any changes in the tumor
induced by therapy. The most challenging problem is that
common registration techniques will compress the breast
tumor imaged before treatment to match the tumor shape
observed after treatment because the tumor shape typically
changes and the tumor size decreases posttreatment. This
kind of compression is misleading in regards to tumor
response. Hence, any longitudinal breast image registration
technique must be able to accommodate changes within
the breast without forcing posttreatment tumor shape and
volume to match pretreatment features.
Chittineni et al. [78] presented a work which used a
B-spline-based method to register longitudinal breast MR
images. To maintain tumor volumes, a rigidity constraint
was imposed on the nonrigid registration. Speciﬁcally, the
B-spline control points that cover the tumor were forced to
remain equidistant during the registration process.
Li et al. [79] proposed another registration method to
a l i g nb r e a s tM Ri m a g e so b t a i n e da td i ﬀerent time points
throughout the course of chemotherapy. The adaptive basis
algorithm (ABA), which can accommodate nonrigid coreg-
istrations, was extended through incorporating a volume-
preserving constraint [80] into the MI-based cost func-
tion. The algorithm was used to register high-resolution
T1-weighted MR images obtained pretreatment, post one
cycle of treatment, and after all cycles of treatment. The
generated transformations were then applied to longitudinal
parametric maps obtained from breast DCE-MRI data. The
alignment of the parameters which were related to tumor
characteristics allowed a voxel-by-voxel-based analysis of
tumor response. Li et al. [81] also developed a realistic
phantom based on biological and clinical observations to
quantitatively and comprehensively evaluate the proposed
registration algorithm. The validation experiments demon-
strated that the proposed method was highly accurate.
Figure 3 presents an example of the performance of the
algorithm. The T1-weighted MR image before neoadjuvant
chemotherapy (panel a) is registered to the image posttreat-
ment (panel d) using the constrained algorithm and the
original ABA algorithm, respectively. The registered image
obtained with the constrained algorithm (panel b) shows
the tumor is preserved successfully, while the original ABA
algorithm compresses the tumor substantially (panel c).
As mentioned above, Ma et al. [55]c o n d u c t e dv o x e l -
by-voxel analyses on ADC maps to evaluate breast cancer
treatment through registering diﬀusion weighted MRI scans
obtained pretreatment, early posttreatment, and late post-
treatment. The registration algorithm [82] used by them
required the user selection of control points. The TPS
transformation mapping two sets of control points was
calculatedand applied to the images and the MI between two
images was then evaluated. The MI-based cost function was
minimized through automatically adjusting the locations of
control points in the optimization process and recalculating
the TPS transformation and the MI iteratively. The voxel-
based analysis showed that ADC changes were able to predict
early breast tumor response to treatment.
Though these are exciting and promising early eﬀorts, we
stressthatlongitudinalregistrationofbreastimagesobtained
at diﬀerent time points is still very much experimental and
much work is left to be done.
5.3. Research Opportunities in Longitudinal Registration of
Breast Images. The paucity of studies relating to longitudinal
registration of breast images leaves many research oppor-
tunities. All current investigations rely on intensity-based
registration algorithms, neglecting the inherent physical
properties of tumor and healthy tissues. One potential
approach is to incorporate breast tissue characteristics into
the registration process. Schnabel et al. [74]c o n s t r u c t e d10 Journal of Oncology
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Figure 3: The T1-weighted MR image before neoadjuvant chemotherapy (a) is registered to the image posttreatment (d) using the
constrained ABA algorithm and the original ABA algorithm, respectively. The registered image using the constrained algorithm (b) shows
that the tumor is preserved successfully, while the original ABA algorithm compresses the tumor substantially (c).
an FEM model which simulated biomechanical tissue defor-
mations to validate a nonrigid registration algorithm, but
the model was applied to pre- and postcontrast breast MR
images, instead of pre- and posttreatment data. In addition
to the challenging problems described above in longitudinal
breast image registration, it is also diﬃcult to measure
tumor and tissue mechanical features on an individual basis
and build patient-speciﬁc models. Furthermore, the breast
tumor generally has diﬀerent material properties before and
after treatment. Solving those diﬃculties may improve the
performance of registration substantially. Another potential
opportunityistheuseofphysiologicalDCE-MRIparameters
during registration. Integrating the parameters related to
tumor features into the registration will possibly improve the
performance of registration.
6. Biomedical Informatics Systems
to SupportImage-Based Treatment
Response Assessment
Current approaches for applying and developing response
criteria have signiﬁcant limitations. In this section, we
describe the current approaches and systems used to apply
and develop response criteria, describe the limitations of
these approaches, existing systems that may oﬀer solutions,
and additional research opportunities.
6.1. Limitations of Current Approaches to Applying Response
Criteria. There are several challenges with the current
approach to manage clinical trial response data and apply
response criteria. First, the raw imaging data are not
routinely stored as part of clinical trial data management
systems. The DICOM (digital imaging and communications
in medicine) image ﬁles are often stored on CDs that can be
shipped to central sites for review or maintained on the local
institution’s PACS (picture archiving and communications
system). As a result, many large multicenter clinical trials
often have incomplete image data sets when it is time to
perform a secondary central review. Second, the current
radiologist-oncologist communication paradigm is not opti-
mally coordinated with respect to tracking target lesions of
interest, resulting in incomplete information for evaluating
tumor response status being recorded in the medical record
[83]. Current reporting of radiology results in the medical
recordfocusesonsummarizingﬁndings,whichisinsuﬃcient
forconsistentapplicationofquantitativemethodstoevaluate
response to treatment.
Furthermore, the use of manually transcribed records of
response has several disadvantages including transcription
errors, ambiguity of lesion identiﬁers when multiple lesions
are present in the same organ or image, lack of a direct
link to the source image data, and limited functionality for
calculating response. Response criteria contain multiple cal-
culation and classiﬁcation rules that are often inconsistently
applied within and across studies. This makes it diﬃcult
to compare trial response outcomes between cohort arms
within the same study and between diﬀerent trials within the
sameclinicaldomain.Automatedinterpretationmethodsare
needed to improve the consistency of response classiﬁcation.
However, manual data collection in unstructured data for-
mats does not facilitate automated data interpretation. The
lack of a direct link between the recorded lesion values and
the raw image data source also makes it diﬃcult for outside
reviewers to audit the response assessment interpretation
results. Finally, there is often a delay in formal application of
response criteria to assist treatment decision making and the
response data are not integrated into the electronic medical
record in such a way that it can readily be used at the point of
care by the treating oncologists. Clinical and clinical research
systems are needed to (1) support the transfer, storage, and
retrieval of clinical and clinical research DICOM ﬁles, (2)
manage the workﬂow for interpretation of image data, (3)
acquire, store, and retrieve image interpretation meta-data,
(4) interpret image ﬁndings for response assessment, and (5)
enable review of image meta-data and their interpretations
with other clinical data as needed for treatment decision
making and the aggregation and auditing of response
outcomes in clinical trials.
6.2. Limitations of Current Approaches to Development of
Response Criteria. Several European and American research
centers are involved in the development and testing of new
oncology response assessment criteria. For the recent update
of the RECIST criteria to version 1.1, a large retrospectiveJournal of Oncology 11
database of target lesion measurements was developed to test
the impact of modiﬁcations to the criteria [84]. Meta-data
on 18,000 potential target lesions were obtained from 6512
patients in 16 metastatic cancer clinical trials. The database
was used to evaluate the impact of changes to RECIST on
the classiﬁcation of patient response to treatment [85]. The
RECIST 1.1 criterion was thus validated only by comparing
it to the previous standard approach and not by evaluating
its correlation with survival endpoints.
The ongoing multicenter I-SPY II (investigation of
serial studies to predict your therapeutic response with
imaging and molecular analysis 2) neoadjuvant breast
cancer clinical trial [86] is attempting to address some
of these issues by evaluating if breast MRI response pre-
dicts treatment outcomes. The NCI’s cancer Biomedical
Informatics Grid (caBIG) (https://cabig.nci.nih.gov/)p r o -
gram is supporting the I-SPY trial through integration
and analysis of diverse data types including clinical, MRI
imaging, and tumor biomarkers throughout the breast
cancer treatment cycle. The integrated platform is designed
to enable correlation of molecular data with MRI pat-
terns to identify surrogate markers for early treatment
response.
Despitetheserecentadvancesinthedevelopmentoflarge
databases to conduct research on response criteria, several
limitations remain. First, these data repositories currently
do not use data standards for sharing imaging metadata
across institutions so as to enable the collection of large
imaging data sets for research. Similarly, there is a lack of
publicly available data sets containing baseline and follow-
up imaging studies and image annotations, along with the
corresponding diagnoses, therapies, and clinical outcomes.
A publicly available database containing data from multiple
institutions could be used to evaluate new image processing
algorithms and response criteria.
6.3. Biomedical Informatics Systems to Support Response
Assessment. Several biomedical informatics systems have
been developed that could support the application and
development of response criteria. These include systems
to support (1) the creation of image repositories, (2) the
acquisition, transfer and storage of image meta-data, (3)
the automated interpretation of response data, and (4) the
visualization of image meta-data for treatment decision
making.
Several systems have been developed to support the
creation of image repositories for clinical research. The
National Biomedical Imaging Archive (NBIA) (https://cabig
.nci.nih.gov/tools/NCIA) provides web-based access to
deidentiﬁed DICOM images, markups, and annotations
using role-based security. Publically available image
collections available though the NBIA include the I-SPY
trial and the Reference Image Database to Evaluate Therapy
Response (RIDER) (https://wiki.nci.nih.gov/display/CIP/
RIDER) which includes serial DCE-MRI studies of the
breast. These publically available image data sets are
available via the NCI hosted NBIA, but institutions can
adapt the open source NBIA software for data storage by
setting up a local instance of NBIA at the institution.
The American College of Radiology Imaging Network
(ACRIN) (http://www.acrin.org/) has developed the TRIAD
(https://triad.acr.org) system to support the management of
largeimagerepositoriesforclinicalresearch.TheTRIADweb
client allows users to search, download, and view available
DICOM image series, while the graphical user interface
client provides advanced functions for DICOM series rout-
ing, image processing, and annotation layer management.
TRIAD is used to manage the image data for all of ACRIN’s
clinical trials but remains proprietary software.
In addition to advances in the management of clinical
trial image data, several more recent advances have emerged
in the management of image meta-data. Image meta-data
refers to data that describe the content of images. Another
initiative of the caBIG program was the development of
the image Physician Annotation Device (iPad) [87]. iPad
is a plugin to the popular open source OsiriX [88]i m a g e
viewing application and implements the Annotation and
Image Markup (AIM) standard [89]. AIM provides the data
structure for storing the key semantic lesion information.
“Semantics” refers to meaning in images including image
metadatapertinenttoquantitativecriteriaofdisease,suchas,
lesion identiﬁcation, location, size measurements, method of
measurement, and other quantitative features. AIM utilizes
the RadLex [90] controlled terminology for describing the
contents of medical images, and provides a standard infor-
mation model for semantic annotations. Information about
image annotations is recorded in AIM as XML compliant
withtheAIMschema,enablingtheconsistentrepresentation,
storage, and transfer of the semantic meaning of imaging
features.
The use of iPad has been recently evaluated for tumor
lesion tracking and semantic annotation of image meta-data
toautomaticallypopulatelesionﬂowsheetsforseveralcancer
clinical trials [91]. The use of a semantic image annota-
tion tool to directly populate lesion ﬂow sheets provides
several advantages. First, the use of an information model
and structured terminology to encode cancer lesion image
ﬁndings provides a consistent representation for storage
and sharing of image meta-data needed for cancer clinical
trials. The information model also provides a foundation to
enable reasoning with and querying over image meta-data
for response assessment. Image annotation disambiguates
lesion identiﬁers by linking them directly to the source image
and image mark-up. Image annotation tools also directly
generate meta-data about image mark-up such as, length
calculations eliminating possible transcription errors for
length measurements.
Automated response assessment methods have also
been developed to calculate RECIST variables such as,
sum of diameters and the percent change from baseline.
For example, a semantic reasoning method for response
assessment utilizing AIM data was recently developed [92].
The method evaluates both the qualitative and quantitative
features of tumor lesion annotations to calculate and clas-
sify treatment response according to the RECIST criteria.
A vendor solution developed by MEDIAN technologies
(http://www.mediantechnologies.com/) includes systems to
measure and track cancer lesions and calculate quantitative12 Journal of Oncology
RECIST metrics. Use of such automated approaches could
improve the consistency and ease with which response
criteria are applied in clinical research and routine care.
The abstraction and visualization of cancer lesion meta-
data have also been demonstrated and integrated into the
clinical work ﬂow of treating medical oncologists [93]. Such
visualizations enable rapid and accurate assessments of the
image-based response data for use in treatment decision-
making. Additional work however, is needed to incorporate
image and response meta-data into the electronic health
record and to integrate them with other clinical data
such as treatments administered and laboratory response
biomarkers.
6.4. Research Opportunities Bioinformatics Systems. We have
described above several existing and emerging informatics
systems that manage various aspects of image-based cancer
treatment response assessment. However, several biomedical
informatics research challenges remain to be solved to
support application and development of response criteria for
breast cancer. One of the greatest challenges remains inte-
gration of these various systems to support end-to-end data
acquisition, interpretation and visualization for clinical trial
data management and treatment decision support. Figure 4
shows an informatics architecture integrating multiple data
acquisition and visualization systems with their respective
data storage systems. Automated response calculators also
needtobeintegratedintosystemstosupportmoreconsistent
application of response criteria.
Research systems are also needed to better support
the development of response criteria for novel imaging
techniques such as DW-MRI and DCE-MRI of the breast.
Large de-identiﬁed data sets are needed of image and
image meta-data linked to patient treatments and clinical
outcomes. While the iSPY trial presents an interesting pilot
of such a system, larger data sets will likely be required to
validate new response assessment modalities and criteria.
7. Breast MRI at3T
For most of the past 20 years, human body imaging has been
performed mainly at 1.5T. In recent years, clinical scanners
operating at the higher ﬁeld of 3T have become routinely
available for clinical studies. To date, 1.5T is still the main
ﬁeld for studies of the breast.
7.1. Motivation for Higher Field Imaging. All magnetic reso-
nance imaging techniques are constrained by a compromise
between temporal and spatial resolution and signal-to-noise
ratio (SNR). The fundamental motivations for high-ﬁeld
breast imaging are (1) a higher SNR, which provides gains
that can then be kept or traded for higher spatial and/or
temporal resolution, and (2) spectral spreading, which
improves the resolution of magnetic resonance spectroscopy
(discussed below in Section 7.3) and can improve fat
suppression. These improvements can, potentially, lead to
shortened acquisition times or increasing sensitivity and
speciﬁcity for DW-MRI and DCE-MRI and, ultimately,
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Figure 4: Biomedical informatics system architecture to support
cancer treatment response assessment. Integrated systems are
needed to support end-to-end management of response assessment
data including data acquisition, analysis, and visualization. Data
acquisition includes systems to acquire and store clinical images
for research as well as systems to create image annotation data
whether manual image annotation or automated image processing
algorithms. Response calculation methods also need to be inte-
grated with structured image annotation databases to perform data
analysis to generate response interpretations. The images, image
annotations, and response interpretations must be integrated with
Clinical Trial Management Systems (CTMS) to enable visualization
of response interpretations for treatment decision-making and
auditing of clinical trial image response data.
better patient care. Unfortunately, direct comparison studies
between 1.5 and 3T are diﬃcult to execute due to the
typically short pre-operative window in breast cancer and
the requirement for a patient to make multiple trips to an
imaging site because separate studies must be performed
on separate days to eliminate image contamination by
previouscontrastmaterial[94].Thus,onlyafewstudieshave
performedsuchadirectcomparison,buttheysuggestthat3T
is at least equivalent, and often better, than 1.5T.
Elsamaloty et al. [95] retrospectively examined sensi-
tivity, speciﬁcity, and predictive values of breast MRI in
434 women and found MRI at 3T to be more sensitive
than mammography and sonography (100% versus 81.8%
and 86.4%, resp.) in detection of breast cancer and charac-
terization of lesions smaller than 4 mm. They also found
that 3T MRI had a higher sensitivity than lower-ﬁeld MRI
(100% versus 71%–94.4% reported for low-ﬁeld studies)
with no signiﬁcant diﬀerence in speciﬁcity. Schmidt et
al. [96] compared FDG-PET-CT to whole-body MRI at
1.5T and 3T and found that whole-body MRI using either
ﬁeld strength gave excellent sensitivity (93%) in detecting
distant metastatic disease in breast cancer patients, but was
less accurate at identifying involved lymph nodes (only 16
of 21 identiﬁed). Overall, they found “comparably good
performance on both scanners with only slightly increasedJournal of Oncology 13
artifacts at 3T, without signiﬁcantly restraining inﬂuence on
image quality” and a shorter scan time at 3T (43 versus
51 min). An interesting example of a 3T breast protocol
was oﬀered by Pinker et al. [97]. Noting the conﬂicting
demands of high temporal resolution imaging (required
for quantitative DCE analysis) and high spatial resolution
(requiredforclinicalreading),theauthorsdesignedanimag-
ing approach that alternates between a T1-weighted volume-
interpolated-breathhold-examination (VIBE) sequence, for
high temporal resolution data, and a T1-weighted fast-
low-angle-shot (FLASH) sequence with fat suppression for
morphologic analysis.
Aﬁ n a l3 Tv e r s u s1 . 5 Ts t u d yw ew i l ld i s c u s sc o m p a r e d
contrast-enhanced imaging of the breast in the same patient
setatthetwoﬁeldstrengths[98].Thegoalofthestudywasto
prospectively compare the the image quality and diagnostic
performance of the data obtained at 3T and 1.5T. Image
quality was (visually) scored from one to ﬁve, with one being
nondiagnostic and ﬁve being excellent. Diﬀerential diagnosis
was assessed by the receiver operator characteristic (ROC)
analysis. Overall image quality was judged to be higher at 3T;
3T received an average score of 4.6 ± 0.5, while 1.5T received
an average score of 4.2 ± 0.5 (P<. 01). This diﬀerence in
image quality translated into an improvement in diagnostic
performance; an ROC score of 0.98 at 3T compared to. 0.84
at 1.5T (P<. 05). The authors were careful to state that
this result should not be read as an indication that contrast-
enhanced breast MRI at 3T is more sensitive or speciﬁc than
at1.5T,buttheydidconcludethatcontrast-enhancedMRIat
3T is beginning to be ready for routine clinical use.
7.2. Challenges for Breast Imaging at 3T. Kuhl reviewed
several issues involved with moving clinical breast imaging
to 3T and stressed the need for maximum SNR [94]. Soher
et al. provide an excellent review of relevant physics involved
in going from 1.5 to 3T [99]. Major barriers to 3T imaging
of the breast include increased B0 and B1 inhomogeneity
(due to shorter RF wavelengths), higher speciﬁc absorption
rate (SAR), changes in relaxation rate (lengthening T1 and
shortening T2, which can adversely aﬀect tissue contrast)
changes, chemical shift artifacts, susceptibility gradients, and
medical device safety. Some of the implications of these
changes are described in more detail below.
As B0 increases, the precession frequencies of nuclear
magnets increase, in turn reducing the eﬃciency of spin-
lattice relaxation processes and a longer persistence of the
longitudinal magnetization. This translates to an increased
T1 relaxation time at 3T. In order to preserve T1 contrast,
al o n g e rT1 would require longer repetition time (TR)
and/or longer inversion delay values which may lead to
lower temporal resolution and/or increased scan times.
T1 values for both adipose and ﬁbroglandular tissue have
been shown to increase by approximately 20% in going
from 1.5T to 3T [100]. This has a proportional eﬀect
on the inversion times used for fat suppression and pro-
vides a good example of sequence parameters that must
change in going to 3T. Additionally, since the relaxivity
of clinically accepted contrast agents decreases with ﬁeld
strength, dosing for DCE-MRI may need to be modiﬁed
from the 1.5T values to achieve comparable contrast at 3T
[101].
SAR scales with the square of the ﬁeld strength, so
all other parameters being equal, the SAR level at 3T is
expected to be four times that at 1.5T. Increased SAR may
require modiﬁcation of pulse sequences, such as smaller
ﬂip angles, longer echo times, or more data (i.e., k-space)
lines acquired per excitation, to reduce RF power deposition
to 1.5T levels, thus compromising some of the SNR and
temporal resolution gains available at 3T.
Increased B1 inhomogeneity due to dielectric eﬀects can
cause spatial variations in SNR. The sensitivity of the overall
scan is limited by the lowest sensitivity of any voxel in the
volume so the overall scan sensitivity suﬀers when there are
signiﬁcant areas of low B1. Azlan et al. have quantiﬁed B1
inhomogeneity across the breast in normal volunteers at 3T
[102]. They ﬁnd a median 40% reduction of the expected
B1 in the right breast on T1-weighted spoiled gradient echo
images.
7.3. Research Opportunities for Breast Imaging at 3T. Main-
taining or improving image characteristics such as, contrast,
resolution,andSNRat3Twillrequirenotonlymodiﬁcations
to conventional sequences but also improved hardware
designs. Larger multichannel coil arrays will help maintain
existing scan times with increased parallel acceleration
factors while maintaining comparable SNR [103].
The stronger background magnetic ﬁeld produces a
wider separation of fat and water frequencies, though this
improvement in spectral resolution is somewhat balanced
by increased susceptibility eﬀects that broaden the lines.
Assuming that the line broadening does not completely
nullify the wider separation of the spectral lines, fat sup-
pression should be more complete at 3T. This gain, plus
the possibility of increased time resolution, could improve
fat-suppressed DW-MRI (important for limiting artifacts)
as well as DCE-MRI studies [104]. However, B0 and B1
inhomogeneity make successful fat suppression diﬃcult in
practice. MR spectroscopy (MRS) is also hampered by the
limited SNR available at 1.5T and could theoretically beneﬁt
from the increased SNR at 3T [105]. Many groups have
employed MRS for measuring the response of tumors to
treatmentandtheinterestedreaderisreferredtotheexcellent
recent reviews in references [106, 107]. In the context of
breast cancer, the MRS-visible molecule that has gener-
ated the most interest is choline. Since choline containing
compounds are implicated in synthesis and metabolism of
cell membranes, the standard interpretation of increases in
total choline signal is increased cell turnover. However, at
lower ﬁelds measuring this signal can be quite diﬃcult and
time consuming which can be a burden on the patient.
It has been established that the sensitivity of proton MRS
scales roughly linearly with ﬁeld strength [108, 109]. Also,
the increased spectral spreading with higher ﬁeld strength
leads to the separation of previously overlapping spectral
peaks and ultimately the ability to resolve and quantify
more compounds. Thus, the use of higher magnetic ﬁelds
oﬀers the opportunity for more precise and shorter MRS
studies.14 Journal of Oncology
Finally, medical devices or implants deemed MR com-
patible at 1.5T may not be at 3T, or they may more markedly
degrade the image quality as ﬁeld strength increases [105].
However, Peters et al. concluded that MRI-guided large-
core needle breast biopsy is safe and eﬀective at 3T, despite
fears over increased susceptibility artifacts from the biopsy
needle [110]. More studies of device safety and eﬀects on
imagequalitymustbedonefortherangeofdevicescurrently
approved for 1.5T use.
8. Summary
Inthispaperwehavehighlightedseveralareasofquantitative
magnetic resonance imaging that will have to be advanced
in order to report with high sensitivity and speciﬁcity on
the response of breast tumors to treatment. While the
current state of the art in quantitative breast MRI is not
quite ready for clinical acceptance, we believe that future
developments in each of these areas will catalyze the use of
more advanced MR techniques for breast cancer imaging.
In fact, there are a number of organizations designed to
assist in these eﬀorts by standardizing various acquisition
and analysis protocol; these include QIBA (Quantitative
Imaging Biomarkers Alliance) and UPICT (Uniform Proto-
cols for Imaging in Clinical Trials). There is also a recent
NCI initiative to encourage the incorporation of emerging
quantitative imaging in clinical trials (and, therefore, larger
controlled patient populations) through the Quantitative
Imaging Network (QIN).
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